28 June - 1 July 2017
Barcelona, Spain

Continuing Education

ESMO-MORA

ESMOThe ESMO 19th World Congress on Gastrointestinal Cancer is accredited by the European Society for Medical Oncology to award 25 Category 1 ESMO-MORA points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology.

ACCME

Physicians

​Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

Imedex, LLC designates this live activity for a maximum of 23.5 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Who Should Attend

This Congress is specifically designed for practicing clinicians, gastroenterologists, hepatologists, pathologists, surgeons, medical oncologists, radiation oncologists, and clinical researchers who wish to review and update their knowledge and management of cancers of the gastrointestinal tract.

Learning Objectives

After attending this Congress, participants should be able to:

  • Identify current controversies in the management of patients with gastric or esophageal cancers
  • Discuss contemporary treatment options for patients with gastric or esophageal cancers
  • Comment on available treatment options for rare gastrointestinal and neuroendocrine tumors
  • Recognize the epidemiology and pathogenesis of hepatocellular carcinoma
  • Discuss management of patients with cancer of the liver
  • Understand adjuvant and neoadjuvant treatment options for patients with locally advanced and metastatic cancer of the pancreas
  • Select the most appropriate detection, screening, and chemoprevention methods for colorectal cancer
  • Generalize the use of molecular markers for screening and prognosis of colorectal cancer and gastric cancer
  • Select the most appropriate adjuvant and neoadjuvant treatments for colorectal cancer patients
  • Comment on new agents in the treatment of colorectal cancer and the latest clinical trials results
  • Identify treatment strategies for rectal cancer
  • Distinguish appropriate surgical techniques for the treatment of gastrointestinal cancers